Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One Patent, Three Patent Applications Related to RNAi: Sep 13, 2007

Premium
Title: Method of Controlling Gene Silencing Using Site-Specific Recombination
 
Number: 7,267,979
 
Filed: June 30, 2003
 
Inventor: Narendra Yadav, Pioneer Hi-Bred
 
“This invention,” the patent’s abstract states, “relates to methods of controlling gene silencing using site-specific recombination. A variety of constructs are provided which are useful for conditional or regulated gene silencing in plants, comprising a suite of constitutive, inducible, tissue-specific, or developmental stage-specific promoters operably linked to target sequences. Recombinase inversion or excision yields double-stranded TS RNA, which thereby functions to trigger endogenous gene silencing mechanisms,” the abstract adds. “By matching promoters, responsive to various inducers, plant tissues, or plant developmental states with the recombinase systems, transcriptional stop fragments or introns and target sequences, gene silencing of virtually any target sequence may be modulated at any plant development stage or in any plant generation. This is especially useful, when genes responsible for gene silencing are down-regulated to permit expression of particular transgenes at levels greater than permitted when gene silencing is activated.”
 

 
Title: siRNA Targeting Minichromosome Maintenance-Deficient 4
 
Number: 20070207491
 
Filed: March 21, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to MCM4.”
 

 
Title: Polymeric Carrier for Delivery of Small Interfering RNA
 
Number: 20070207966
 
Filed: March 3, 2006
 
Lead Inventor: Won Jong Kim, University of Utah
 
The patent application, its abstract states, claims “a carrier for delivering small interfering RNA into cells [that] includes a cholesterol residue covalently bonded to oligoarginine. Mixing the siRNA with the carrier produces a complex-containing composition. Contacting a cell with the complex-containing composition results in delivery of the siRNA into the cell. Delivery of an siRNA targeted to vascular endothelial growth factor is a treatment for cancer. Methods of making the carrier and complex are also disclosed,” the abstract adds.
 

 
Title: Functional and Hyperfunctional siRNA
 
Number: 20070207974
 
Filed: March 30, 2005
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
According to the patent application’s abstract, “efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.”

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.